Nature Communications (Dec 2022)

A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes

  • Jawaher Alharthi,
  • Ali Bayoumi,
  • Khaled Thabet,
  • Ziyan Pan,
  • Brian S. Gloss,
  • Olivier Latchoumanin,
  • Mischa Lundberg,
  • Natalie A. Twine,
  • Duncan McLeod,
  • Shafi Alenizi,
  • Leon A. Adams,
  • Martin Weltman,
  • Thomas Berg,
  • Christopher Liddle,
  • Jacob George,
  • Mohammed Eslam

DOI
https://doi.org/10.1038/s41467-022-35158-9
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 19

Abstract

Read online

Hyperactivation of the toll-like receptors (TLRs) have been implicated as risk factors for more severe forms of disease in COVID-19 and metabolic (dysfunction) associated fatty liver disease (MAFLD). Here the authors report that MBOAT7 is reduced in macrophages of patients with MAFLD and COVID-19, and acts as a negative regulator of TLR signalling.